Investors might want to bet on Astrana Health, Inc. (ASTH) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a c ...

Core Viewpoint - Cadence (CADE) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on earnings estimates, leading to significant stock price movements when they buy or sell large amounts of shares [4]. Cadence's Earnings Outlook - The upgrade for Cadence reflects an improvement in the company's underlying business, which is expected to drive the stock price higher as investors recognize this trend [5][10]. - For the fiscal year ending December 2025, Cadence is projected to earn $2.92 per share, with a 5.9% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10].

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.3% loss over the past four weeks.The stock rallied after the company announced positive top-line data from a phase II study evaluating its investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, in patients with acquired hypothalamic obesity. ...

Core Viewpoint - Kennedy-Wilson (KW) has shown a significant price increase of 11.3% over the past four weeks, with a mean price target of $9.9 indicating a potential upside of 32.7% from the current price of $7.46 [1] Price Targets and Analyst Consensus - The average price targets for KW range from a low of $7.70 to a high of $13.00, with a standard deviation of $2.76, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 3.2% increase, while the highest suggests a 74.3% upside, highlighting the potential for significant price movement [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about KW's earnings prospects, with a strong consensus on revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 245.5% over the past month, indicating positive sentiment among analysts [12] - KW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, further supporting its potential upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead, as empirical research shows that they rarely predict actual stock price movements accurately [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Red Robin (RRGB) has shown an 8.1% increase in stock price over the past four weeks, with a mean price target of $9.38 indicating a potential upside of 49.1% from the current price of $6.29 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.94, where the lowest estimate is $3.50 (44.4% decline) and the highest is $12.00 (90.8% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about RRGB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 14.5%, with one estimate moving higher and no negative revisions [12] - RRGB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Vir Biotechnology, Inc. (VIR) shares soared 11.9% in the last trading session to close at $5.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.2% loss over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Vir Biotechnology’s only late-stage pipeline candidate, tobevibart. It is being developed in combination with Alnylam’s elebsiran, in a regi ...

TopBuild (BLD) shares soared 6.1% in the last trading session to close at $378.8. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.3% gain over the past four weeks.TopBuild shares rose after announcing an $810 million cash deal to acquire Progressive Roofing, a Bow River Capital portfolio company. The acquisition is expected to provide TopBuild with a strong platform to enter the commercial roofing segment. Progressive Roofing ...

Analysts on Wall Street project that State Street Corporation (STT) will announce quarterly earnings of $2.36 per share in its forthcoming report, representing an increase of 9.8% year over year. Revenues are projected to reach $3.37 billion, increasing 5.7% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 4.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates d ...

Core Viewpoint - BlackRock is expected to report quarterly earnings of $10.77 per share, a 4% increase year-over-year, with revenues projected at $5.38 billion, reflecting a 12% year-over-year growth [1]. Earnings Estimates - Wall Street analysts have revised the consensus EPS estimate upward by 1.7% over the last 30 days, indicating a collective reassessment of forecasts [2]. - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3]. Revenue Projections - Analysts project 'Revenue- Technology services revenue' at $493.72 million, a year-over-year increase of 25% [5]. - 'Revenue- Advisory and other revenue' is expected to reach $59.44 million, reflecting a 12.1% year-over-year increase [5]. - 'Revenue- Investment advisory performance fees' is forecasted at $156.55 million, indicating a year-over-year decline of 4.6% [5]. - The consensus for 'Revenue- Distribution fees' is $323.27 million, a 1.7% year-over-year increase [6]. - 'Revenue- Total investment advisory, administration fees and securities lending revenue' is expected to be $4.36 billion, showing a 12.6% year-over-year growth [6]. Assets Under Management - 'Assets under management - Cash management' is projected at $771.17 billion, down from $778.04 billion year-over-year [7]. - 'Total Assets Under Management' is expected to reach $11,679.24 billion, up from $10,645.72 billion in the same quarter last year [7]. - 'Assets under management - Long-term' is forecasted at $10,762.03 billion, compared to $9,867.68 billion in the same quarter last year [8]. - 'Assets under management - ETFs' is estimated at $4,295.42 billion, up from $3,855.77 billion year-over-year [9]. Net Inflows - 'Net inflows - Product Type - Cash management' is projected to be $66.79 billion, compared to $30.20 billion year-over-year [8]. - 'Net inflows' are expected to reach $124.01 billion, up from $81.57 billion in the same quarter last year [9]. - 'Net inflows - Client Type - ETFs' is estimated at $57.88 billion, down from $83.14 billion in the same quarter last year [10]. Stock Performance - BlackRock shares have increased by 9.6% over the past month, outperforming the Zacks S&P 500 composite's 4.4% increase [11].

In its upcoming report, JB Hunt (JBHT) is predicted by Wall Street analysts to post quarterly earnings of $1.34 per share, reflecting an increase of 1.5% compared to the same period last year. Revenues are forecasted to be $2.96 billion, representing a year-over-year increase of 1.1%.The current level reflects a downward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial proje ...